Coiled Therapeutics plc

COIL · LSE · Healthcare / Biotechnology

6.75GBX+0.00 (0.00%)

Price History

Full chart

Market Stats

Previous Close6.75

Open6.75

Day Range6.75 – 6.85

52-Week Range6.75 – 30.00

Volume76.46K

Market Cap30.94M

P/E (TTM)0.00

Forward P/E0.00

EPS-0.20

Dividend Yield0.00%

50-Day Avg8.89

200-Day Avg9.80

About

Coiled Therapeutics plc, a clinical-stage oncology company, develops and commercialises clinical-stage oncology therapeutics in the United Kingdom and internationally. The company's lead asset is AO-252, a first-in-class, small molecule inhibitor of TACC3, currently in a Phase I clinical trial for advanced solid tumours, including ovarian and prostate cancer. The company also offers a STAT-6 siRNA programme targeting immunology indications such as asthma, fibrosis, eczema, and allergic disease, with plans for assessment towards Phase I clinical trials. The company is based in London, United Kingdom.

Company Details

SectorHealthcare
IndustryBiotechnology
CEOMr. Sridhar Vempati MBA, Ph.D.
Headquarters167-169 Great Portland Street, London, United Kingdom, W1W 5PF, UK
Websitehttps://coiledplc.com

Leadership

Dr. Sotirios G. Stergiopoulos M.D., MBEEExecutive Chairman · b. 1971
Mr. Sridhar Vempati MBA, Ph.D.CEO & Director · b. 1977
Ms. Chaemin Lim Ph.D.Chief Technology Officer
Ms. Robbin Frnka B.S.Chief Clinical Operations

Financials

Income Statement

Currency: GBP	2022-12-31	2023-12-31	2024-12-31	2025-12-31
Total Revenue	0	200.00K	0	0
Growth (%)	-	-	-100.00%	-
Cost of Revenue	0	0	16.00K	0
Gross Profit	0	200.00K	-16.00K	0
Gross Margin	-	100.00%	-	-
Operating Expense	1.63M	2.13M	1.10M	821.96K
Operating Income	-1.63M	-1.93M	-1.12M	-821.96K
Operating Margin	-	-966.82%	-	-
EBITDA	-1.63M	-1.93M	-1.16M	-3.36M
EBITDA Margin	-	-964.14%	-	-
Net Income	-1.62M	-1.74M	-971.80K	-3.36M
Net Income Margin	-	-872.27%	-	-
R&D	319.31K	620.16K	152.91K	149.53K
R&D as % of Total Revenue	-	310.08%	-	-
Interest Expense	0	58	44.86K	37.97K
Interest Expense % of Total Revenue	-	0.03%	-	-

Balance Sheet

Currency: GBP	2022-12-31	2023-12-31	2024-12-31	2025-12-31
Total Assets	7.77M	6.09M	5.75M	2.69M
Total Liabilities	561.58K	589.02K	861.73K	273.42K
Total Equity	7.21M	5.50M	4.89M	2.42M
Cash	2.32M	537.32K	337.11K	78.05K
Net Debt	-	-	62.98K	-

Cash Flow

Currency: GBP	2022-12-31	2023-12-31	2024-12-31	2025-12-31
Operating Cash Flow	-1.58M	-1.73M	-783.73K	-645.62K
Capital Expenditure	0	54.04K	0	0
Free Cash Flow	-1.58M	-1.79M	-783.73K	-645.62K
FCF to OCF	100.00%	103.12%	100.00%	100.00%

Key Statistics & Ratios

Market Cap30.94M

Enterprise Value33.00M

Trailing P/E0.00

Forward P/E0.00

Price / Sales23.25

Price / Book13.67

EPS-0.20

Revenue (TTM)0

Gross Profit (TTM)0

Profit Margin0.00%

Operating Margin0.00%

Return on Equity0.00%

Return on Assets0.00%

Shares Outstanding426.79M

Shares Float0

Dividend Yield0.00%

Dividend Rate0.00

Payout Ratio0.00%

Stock Splits

Mar 27, 20261:10